Trial Profile
The study of long term morbidity of ombitasvir/paritaprevir/ritonavir and dasabuvir in patients with hepatitis C virus infections.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Aug 2015
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 13 Aug 2015 New trial record